Arbacia Lixula – Holistic Therapy for Diabetes Mellitus using Natural Compounds, Biosensors, and Telemedicine
Description: Sophisticated innovation of natural compounds from Arbacia lixula coelomic fluid peptide targeting AKT1, EGFR, and VEGFR2 protein integrated with SWEETELE telemedicine and non-invasive biosensors (AuNNs) as a holistic therapy for diabetes mellitus in achieving SDGs 2030.
Diabetes Mellitus (DM) is a chronic disease characterized by hyperglycemia, caused by impaired insulin secretion or action. It affects hundreds of millions globally and requires continuous management and monitoring. The proposed innovation explores a novel multi-target therapy for DM using peptides derived from the coelomic fluid of Arbacia lixula (a species of sea urchin), integrated with Sweetele telemedicine and a non-invasive biosensor system (AuNNs). Key Components: Peptide Therapy from Arbacia lixula: The peptides show blood glucose-regulating activity and act as natural ligands for ATP-binding proteins such as AKT1, EGFR, and VEGFR2. These proteins play crucial roles in glucose metabolism, insulin signaling, and vascular health. Peptide analysis (using ToxinPred and AllerTOP) confirmed that peptides B, E, F, and G are non-toxic and non-allergenic. In Silico Analysis: Molecular docking was performed using 3D structures from PubChem and PDB databases. The coelomic peptides demonstrated strong binding affinity and bioactivity toward the selected receptors involved in DM pathogenesis. Biosensor (AuNNs): The non-invasive biosensor system is designed to detect blood sugar through sweat, using gold nanoparticles (AuNNs), graphene oxide, and polyaniline integrated with microfluidic modules and Bluetooth-enabled wearable devices (smartwatch form factor). Sweetele Telemedicine App: A user-friendly mobile application that facilitates continuous remote glucose monitoring, specialist consultations, data visualization, and treatment reminders. It ensures improved adherence to therapy and empowers patients to manage their condition actively. Highlights: Combines natural peptide therapy with modern wearable biosensors and digital health tools. Offers a holistic and economical alternative to conventional diabetes treatments. Aims to contribute to the Sustainable Development Goals (SDGs) 2030, particularly in affordable healthcare and technological innovation.
Organisation: Andalas University, Faculty of Medicine
Innovator(s): Farhan Aqsha Alghani, Khairun Nisa, M. Rifqi Al Azim, Rizka Fauziah, Muhammad Raifa A., M. Ardhan H, Emia Yesa B., Siti Faiza A. , M. Razan Rizkirahman Z
Category: Medicine, Biotechnology and Medical Devices
Country: Indonesia
